Department of Molecular Immunology, Institute of Basic Medical Sciences, Beijing, P.R. China.
Mol Ther. 2013 Sep;21(9):1668-77. doi: 10.1038/mt.2013.90. Epub 2013 Jul 23.
Targeting the adaptor protein (transforming growth factor-β (TGF-β)-activated protein kinase 1 (TAK1)-binding protein 1) (TAB1)-mediated non-canonical activation of p38α to limit ischemia/reperfusion (I/R) injury after an acute myocardial infarction seems to be attractive since TAB1/p38α interaction occurs specifically in very limited circumstances and possesses unique structural basis. However, so far no TAB1/p38α interaction inhibitor has been reported due to the limited knowledge about the interfaces. In this study, we sought to identify key amino acids essential for the unique mode of interaction with computer-guided molecular simulations and molecular docking. After validation of the predicted three-dimensional (3-D) structure of TAB1/p38α complex, we designed several peptides and evaluated whether they could block TAB1/p38α interaction with selectivity. We found that a cell-permeable peptide worked as a selective TAB1/p38α interaction inhibitor and decreased myocardial I/R injury. To our knowledge, this is the first TAB1/p38α interaction inhibitor.
靶向衔接蛋白(转化生长因子-β(TGF-β)-激活蛋白激酶 1(TAK1)结合蛋白 1)(TAB1)介导的非典型 p38α 激活,以限制急性心肌梗死后的缺血/再灌注(I/R)损伤似乎很有吸引力,因为 TAB1/p38α 相互作用仅在非常有限的情况下特异性发生,并具有独特的结构基础。然而,由于对界面的了解有限,到目前为止还没有报道 TAB1/p38α 相互作用抑制剂。在这项研究中,我们试图通过计算机引导的分子模拟和分子对接来识别对独特相互作用模式至关重要的关键氨基酸。在验证 TAB1/p38α 复合物的预测三维(3-D)结构后,我们设计了几种肽并评估它们是否具有选择性阻断 TAB1/p38α 相互作用的能力。我们发现一种细胞通透性肽可作为选择性 TAB1/p38α 相互作用抑制剂,并减少心肌 I/R 损伤。据我们所知,这是第一个 TAB1/p38α 相互作用抑制剂。